DOCSLIB.ORG

Bioavailability and Corneal Anti-Inflammatory Effect of Topical Suprofen

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bioavailability and Corneal Anti-Inflammatory Effect of Topical Suprofen 628 INVESTIGATIVE OPHTHALMOLOGY 6 VISUAL SCIENCE / April 1986 Vol. 27 but only delayed excystation of A. polyphaga organ- 5. Hirst LW, Green WR, Merz W, Kaufman C, Visvesvara GS, isms. The reason for the apparent greater effectiveness Jensen A, and Howard M: Management of Acanthamoeba ker- of this system over the other two chemical disinfection atitis. A case report and review of the literature. Ophthalmology 91:1105, 1984. systems is not clear. It is also unclear whether different 6. Samples JR, Binder PS, Luibel FJ, Font RL, Visvervara GS, and strains of Acanthamoeba species would be variably Peter CR: Acanthamoeba keratitis possibly acquired from a hot susceptible to these disinfection systems. However, re- tub. Arch Ophthalmol 102:707, 1984. sults of this study indicate that heat disinfection was 7. Sculley RE, Mark EJ, and McNeely BU: Case records of the more effective overall in killing Acanthamoeba tro- Massachusetts General Hospital. N Engl J Med 312:634, 1985. 8. Blackman HJ, Rao NA, Lemp MA, and Visvesvara GS: Acanth- phozoites and cysts as compared to cold disinfection amoeba keratitis successfully treated with penetrating kerato- systems. plasty: suggested immunogenic mechanisms of action. Cornea Key words: Acanthamoeba, keratitis, soft contact lens, dis- 3:125, 1984. infection 9. Cohen EJ, Buchanan HW, Laughrea PA, Adams CP, Galentine PG, Visvesvara GS, Folberg R, Arentsen JJ, and Laibson PR: From the National Eye Institute,* Bethesda, Maryland, and De- Diagnosis and management of Acanthamoeba keratitis. Am J partments of Ophthalmology! and Microbiology,^ Cleveland Clinic Ophthalmol 100:389, 1985. Foundation, Cleveland, Ohio, and the Centers for Disease Control,§ 10. Moore MB, McCulley JP, Luckenbach M, Gelender H, Newton Atlanta, Georgia. Submitted for publication: August 14, 1985. Reprint C, McDonald MB, and Visvervara GS: Acanthamoeba keratitis requests: David Meisler, MD, Department of Ophthalmology, associated with soft contact lenses. Am J Ophthalmol 100:396, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 1985. 44106. 11. Krachmer JH and Purcell JJ Jr: Bacterial corneal ulcers in cos- metic soft contact lens wearers. Arch Ophthalmol 96:57, 1978. References 12. Yamamoto GK, Pavan-Langston D, Stowe GC, and Albert DM: 1. Visvesvara GS: Free-living pathogenic amoebae. In Manual of Fungal invasion of a therapeutic soft contact lens and cornea. Clinical Microbiology, 3rd ed, Lennette EH, Balows A, Hausler Ann Ophthalmol 11:1731, 1979. WJ, and Truant JP, editors, Washington, DC, American Society 13. Wilson LA, Schlitzer RL, and Ahearn DG: Pseudomonas corneal for Microbiology, 1980, pp. 704-708. ulcers associated with soft contact lens wear. Am J Ophthalmol 2. Culbertson CG: Pathogenic Acanthamoeba (Hartmannella). Am 92:546, 1981. JClinPathol 35:195, 1961. 14. Myrowitz E, Pearlman P, and Goldberg HK: A case of Pseu- 3. Page FC: Re-definition of the genus Acanthamoeba with descrip- domonas keratitis in a soft contact lens wearer using contami- tions of three species. J Protozool 14(4):709, 1967. nated chemical disinfection solution. Contact Intraocul Lens Med 4. Nagington J and Richards JE: Chemotherapeutic compounds J7(4):337, 1981. and Acanthamoebae from eye infections. J Clin Pathol 29:648, 15. Freedman H and Sugar J: Pseudomonas keratitis following cos- 1976. metic soft lens wear. Contact Lens Journal 10:21, 1976. Bioavailability and Corneal Anti-Inflammatory Effect of Topical Suprofen Howard M. Leibowirz,* William J. Ryan,* Allan Kupferman,*f and Louis DeSanrisJ The bioavailability in rabbit cornea and aqueous humor of an centrations of suprofen when administered according to this ophthalmic formulation of suprofen, a nonsteroidal anti-in- regimen. Invest Ophthalmol Vis Sci 27:628-631, 1986 flammatory drug, was evaluated following topical adminis- tration of a single dose to the eye. The drug penetrated rapidly into the uninflamed cornea with intact epithelium; highest Locally administered corticosteroids effectively sup- levels occurred during the first 30 to 45 min after instillation press corneal inflammation, but their use carries the and decreased thereafter. The bioavailability of suprofen in risk of several ocular complications, including cataract, cornea and aqueous humor following administration of a 1.0% glaucoma, and the enhancement of actively replicating concentration was twice that produced by a 0.5% concentration herpes simplex virus. This has prompted the search for of the drug. Topical application of multiple doses of suprofen other effective but potentially less toxic compounds. failed to suppress polymorphonuclear leukocyte invasion of We have studied suprofen, a nonsteroidal anti-inflam- the cornea if treatment was started after the induction of in- matory agent, and report here our data on its bioavail- flammation. Suprofen therapy initiated prior to the induction of corneal inflammation and maintained into the post-inflam- ability and anti-inflammatory effectiveness in the cor- mation period did produce a significant (P < 0.01) decrease nea following topical administration to the rabbit eye. in the numbers of PMNs that invaded the inflamed cornea. Materials and Methods. Bioavailability studies: So- There was no significant difference (P > 0.05) in the corneal dium thiamylal was administered intravenously to New anti-inflammatory effect achieved by the 0.5% and 1.0% con- Zealand albino rabbits (1.8-2.4 kg), producing light Downloaded from iovs.arvojournals.org on 09/29/2021 No. 4 Reports 629 anesthesia for approximately 10 min and allowing op- Table 1. Mean concentration of suprofen following timal control of the administration of radiolabeled topical application to the normal rabbit cornea* drug. A single 0.05-ml dose of 3H-suprofen 0.5% (17.6 Cornea (fig/gm) Aqueous humor (iig/ml) AtCi/mg) or 1.0% (16.0 /iCi/mg) was placed on the cen- Time tral corneal surface (epithelium intact) of both non- (min) 0.5% 1.0% 0.5% 1.0% inflamed eyes using a microsyringe. The 0.05-ml dose was contained within the conjunctival sac while the 5 17 (±3) 25 (±5) 0.076 (±0.007) 0.192 (±0.031) 15 11 (±3) 18 (±3) 0.120 (±0.015) 0.719 (±0.020) lids were manually blinked three times and taped 30 14(±l)t 22 (±4)f 0.514 (±0.014) 1.342 (±0.271) closed. At fixed times thereafter animals were killed by 45 10 (±2) 16 (±4) 0.673 (±0.018)* 0.863 (±0.250) intracardiac pentobarbital sodium; three saline-soaked, 60 7(±l)t 6 (±2)f 0.508 (±0.047) 1.570 (±0.346)§ 120 4(±1) 10(±l) 0.354 (±0.044) 0.699 (±0.146)§ cotton-tipped applicators, followed by a dry, cotton- 240 4(±D 6(±1) 0.279 (±0.023) 0.430 (±0.038) tipped applicator, were gently rolled over the corneal 360 2(±1) 6(±D 0.151 (±0.019) 0.238 (±0.030) surface to remove radiolabeled surface contaminants. * Table entries are the arithmetic mean (±SEM) of data derived from six This procedure did not disrupt the epithelium, as de- uninflamed eyes with intact epithelium following topical application of a single 0.05-ml dose. Only one eye of an animal was used to obtain data for a given termined by biomicroscopic observation and fluores- time period. cein staining. t 60-minute value is significantly less (P < 0.01) than the 30-min value in the same column. An aqueous humor sample was aspirated from the % Peak value—significantly greater (P < 0.05) than all other values in the anterior chamber with a 27-gauge needle attached to same column. a tuberculin syringe, and an 8-mm full thickness central § The 120-min value is significantly less (P < 0.05) than 60-min value. corneal specimen was obtained by trephination. The corneal samples were weighed and dissolved in 1.5 ml of 0.5N quaternary ammonium hydroxide in toluene PMN invasion of the inflamed cornea was examined (Soluene 100, Packard Instruments; Downers Grove, both when treatment was initiated after induction of IL) at 37 °C over a 24-hr period. Each sample was acid- inflammation and when treatment was initiated prior ified with 0.2 ml concentrated HC1 to eliminate che- to inflammation and continued after induction of the miluminescence produced by the Soluene. Thereafter inflammatory event. Each regimen is outlined in Table the corneal and aqueous samples were handled iden- 4. A control group treated with suprofen vehicle (a tically. Each was diluted with 15 ml of scintillation proprietary buffered ophthalmic vehicle containing counting solution (Ultrafluor, National Diagnostics; preservative and xanthine derivatives) was run with Somerville, NJ) and counted for a minimum of 10 each experimental trial. One hour after completion of min in a Packard 460C scintillation spectrometer. The each treatment protocol a 10-mm full thickness corneal corrected counts per minute were then converted and button was removed by trephination, and the tissue samples were solubilized with a commercially available expressed as micrograms of suprofen per gram of cor- solubilizing agent (Soluene 100, Packard), as described neal tissue or per milliliter of aqueous humor. The final above. The soluble samples were counted for a mini- figure reported for each designated time period is based mum of 10 min, quantitatively measuring the amount on data from six eyes collected in a minimum of two of radioactivity in the cornea. The specific calculations individual experimental trials. The geometric mean was used to determine the data have been reported.1 Sta- plotted as a function of time, a smooth curve was con- tistical evaluation of the data was performed primarily structed, and the area under the curve was determined with analysis of variance using the Scheffe test. This by use of the trapezoid rule. The area thus obtained investigation conformed to the ARVO Resolution on was used to determine the ability of suprofen, with The Use of Animals in Research. time, to concentrate in the cornea and aqueous humor.
Load more

Recommended publications
  • United States Patent (19) 11 Patent Number: 5,955,504 Wechter Et Al
    USOO5955504A United States Patent (19) 11 Patent Number: 5,955,504 Wechter et al. (45) Date of Patent: Sep. 21, 1999 54 COLORECTAL CHEMOPROTECTIVE Marnett, “Aspirin and the Potential Role of Prostaglandins COMPOSITION AND METHOD OF in Colon Cancer, Cancer Research, 1992; 52:5575–89. PREVENTING COLORECTAL CANCER Welberg et al., “Proliferation Rate of Colonic Mucosa in Normal Subjects and Patients with Colonic Neoplasms: A 75 Inventors: William J. Wechter; John D. Refined Immunohistochemical Method.” J. Clin Pathol, McCracken, both of Redlands, Calif. 1990; 43:453-456. Thun et al., “Aspirin Use and Reduced Risk of Fatal Colon 73 Assignee: Loma Linda University Medical Cancer." N Engl J Med 1991; 325:1593-6. Center, Loma Linda, Calif. Peleg, et al., “Aspirin and Nonsteroidal Anti-inflammatory Drug Use and the Risk of Subsequent Colorectal Cancer.” 21 Appl. No.: 08/402,797 Arch Intern Med. 1994, 154:394–399. 22 Filed: Mar 13, 1995 Gridley, et al., “Incidence of Cancer among Patients With Rheumatoid Arthritis J. Natl Cancer Inst 1993 85:307-311. 51) Int. Cl. .......................... A61K 31/19; A61K 31/40; Labayle, et al., “Sulindac Causes Regression Of Rectal A61K 31/42 Polyps. In Familial Adenomatous Polyposis” Gastroenterol 52 U.S. Cl. .......................... 514/568; 514/569; 514/428; ogy 1991 101:635-639. 514/416; 514/375 Rigau, et al., “Effects Of Long-Term Sulindac Therapy On 58 Field of Search ..................................... 514/568, 570, Colonic Polyposis” Annals of Internal Medicine 1991 514/569, 428, 416, 375 11.5:952-954. Giardiello.et al., “Treatment Of Colonic and Rectal 56) References Cited Adenomas With Sulindac In Familial Adenomatous Poly U.S.
    [Show full text]
  • Download Download
    MM Matin et al. Medical Research Archives vol 8 issue 7. Medical Research Archives RESEARCH ARTICLE 2e`1 PASS Predication, Antiviral, in vitro Antimicrobial, and ADMET Studies of Rhamnopyranoside Esters Authors Mohammed M Matin1, Mohammad HO Roshid2, Sreebash C Bhattacharjee3 and Abul KMS Azad4 Affiliations 1 Bioorganic & Medicinal Chemistry Laboratory, Department of Chemistry, University of Chittagong, Chattogram-4331, Bangladesh 2 Department of Anaesthesia and Intensive Care Medicine, Chattogram Medical College, Chattogram- 4203, Bangladesh 3 Chemical Research Division, Bangladesh Council of Scientific & Industrial Research (BCSIR) Laboratories, Chattogram-4220, Bangladesh 4 Department of Chemistry, Chattogram Govt. College, Chattogram-4203, Bangladesh Corresponding Author: MM Matin E-mail address: [email protected] Tel.: +88 01716 839689. Abstract Sugar derived esters (SEs) with potential antimicrobial activity were found to be a better choice to solve the multidrug resistant (MDR) pathogens due to improved antimicrobial efficacy, biodegradability, non-toxic, and non-allergic properties. In this context, a series of benzyl -L- rhamnopyranoside esters with different chain length (C2-C18) were employed for PASS predication, antiviral, and in vitro antimicrobial activity test. The in vitro antimicrobial tests against four bacterial, and four fungal pathogens along with PASS predication indicated that these sugar esters acted as better antifungals as compared to antibacterial functionality. The study revealed that the incorporation of octanoyl (C8) and lauroyl (C12) group(s) at C-3 position of rhamnopyranoside possessed promising antimicrobial, and anti-carcinogenic potentiality with good pharmacokinetic (pkCSM), and drug likeness properties. Also, attachment of multiple ester groups enhanced various drug likeness, and medicinal chemistry friendliness conditions. Overall, the present findings might be useful for the development of rhamnopyranoside based novel MDR antimicrobial drugs.
    [Show full text]
  • B-Lactams: Chemical Structure, Mode of Action and Mechanisms of Resistance
    b-Lactams: chemical structure, mode of action and mechanisms of resistance Ru´ben Fernandes, Paula Amador and Cristina Prudeˆncio This synopsis summarizes the key chemical and bacteriological characteristics of b-lactams, penicillins, cephalosporins, carbanpenems, monobactams and others. Particular notice is given to first-generation to fifth-generation cephalosporins. This review also summarizes the main resistance mechanism to antibiotics, focusing particular attention to those conferring resistance to broad-spectrum cephalosporins by means of production of emerging cephalosporinases (extended-spectrum b-lactamases and AmpC b-lactamases), target alteration (penicillin-binding proteins from methicillin-resistant Staphylococcus aureus) and membrane transporters that pump b-lactams out of the bacterial cell. Keywords: b-lactams, chemical structure, mechanisms of resistance, mode of action Historical perspective Alexander Fleming first noticed the antibacterial nature of penicillin in 1928. When working with Antimicrobials must be understood as any kind of agent another bacteriological problem, Fleming observed with inhibitory or killing properties to a microorganism. a contaminated culture of Staphylococcus aureus with Antibiotic is a more restrictive term, which implies the the mold Penicillium notatum. Fleming remarkably saw natural source of the antimicrobial agent. Similarly, under- the potential of this unfortunate event. He dis- lying the term chemotherapeutic is the artificial origin of continued the work that he was dealing with and was an antimicrobial agent by chemical synthesis [1]. Initially, able to describe the compound around the mold antibiotics were considered as small molecular weight and isolates it. He named it penicillin and published organic molecules or metabolites used in response of his findings along with some applications of penicillin some microorganisms against others that inhabit the same [4].
    [Show full text]
  • Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis
    REVIEW published: 03 July 2018 doi: 10.3389/fmicb.2018.01367 Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis Diana Machado 1, Miriam Girardini 2, Miguel Viveiros 1* and Marco Pieroni 2* 1 Global Health and Tropical Medicine, GHTM, Instituto de Higiene e Medicina Tropical, IHMT, Universidade Nova de Lisboa, UNL, Lisbon, Portugal, 2 P4T Group, Department of Food and Drug, University of Parma, Parma, Italy The emergence of multi- and extensively drug resistant tuberculosis worldwide poses a great threat to human health and highlight the need to discover and develop new, effective and inexpensive antituberculosis agents. High-throughput screening assays Edited by: against well-validated drug targets and structure based drug design have been employed Fernando Rogerio Pavan, to discover new lead compounds. However, the great majority fail to demonstrate any Universidade Estadual Paulista Júlio de Mesquita Filho (UNESP), Brazil antimycobacterial activity when tested against Mycobacterium tuberculosis in whole-cell Reviewed by: screening assays. This is mainly due to some of the intrinsic properties of the bacilli, Pedro Almeida Silva, such as the extremely low permeability of its cell wall, slow growth, drug resistance, Fundação Universidade Federal do drug tolerance, and persistence. In this sense, understanding the pathways involved Rio Grande, Brazil Luiz Augusto Basso, in M. tuberculosis drug tolerance, persistence, and pathogenesis, may reveal new Pontifícia Universidade Católica do Rio approaches for drug development. Moreover, the need for compounds presenting a Grande do Sul, Brazil novel mode of action is of utmost importance due to the emergence of resistance not *Correspondence: Miguel Viveiros only to the currently used antituberculosis agents, but also to those in the pipeline.
    [Show full text]
  • Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery
    International Journal of Molecular Sciences Review Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery Qingxin Li 1,* and CongBao Kang 2,* 1 Guangdong Provincial Engineering Laboratory of Biomass High Value Utilization, Guangdong Provincial Bioengineering Institute (Guangzhou Sugarcane Industry Research Institute), Guangdong Academy of Sciences, Guangzhou 510316, China 2 Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, Chromos, #05-01, Singapore 138670, Singapore * Correspondence: [email protected] (Q.L.); [email protected] (C.K.); Tel.: +86-020-84168436 (Q.L.); +65-64070602 (C.K.) Received: 12 June 2020; Accepted: 20 July 2020; Published: 24 July 2020 Abstract: Small-molecule drugs are organic compounds affecting molecular pathways by targeting important proteins. These compounds have a low molecular weight, making them penetrate cells easily. Small-molecule drugs can be developed from leads derived from rational drug design or isolated from natural resources. A target-based drug discovery project usually includes target identification, target validation, hit identification, hit to lead and lead optimization. Understanding molecular interactions between small molecules and their targets is critical in drug discovery. Although many biophysical and biochemical methods are able to elucidate molecular interactions of small molecules with their targets, structural biology is the most powerful tool to determine the mechanisms of action for both targets and the developed compounds. Herein, we reviewed the application of structural biology to investigate binding modes of orthosteric and allosteric inhibitors. It is exemplified that structural biology provides a clear view of the binding modes of protease inhibitors and phosphatase inhibitors.
    [Show full text]
  • Suprofen | Medchemexpress
    Inhibitors Product Data Sheet Suprofen • Agonists Cat. No.: HY-B0270 CAS No.: 40828-46-4 Molecular Formula: C₁₄H₁₂O₃S • Molecular Weight: 260.31 Screening Libraries Target: PGE synthase Pathway: Immunology/Inflammation Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro DMSO : ≥ 100 mg/mL (384.16 mM) * "≥" means soluble, but saturation unknown. Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 3.8416 mL 19.2079 mL 38.4157 mL Stock Solutions 5 mM 0.7683 mL 3.8416 mL 7.6831 mL 10 mM 0.3842 mL 1.9208 mL 3.8416 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (9.60 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (9.60 mM); Clear solution 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (9.60 mM); Clear solution BIOLOGICAL ACTIVITY Description Suprofen (TN-762) is a non-steroidal anti-inflammatory drug (NSAID). IC₅₀ & Target PGE synthase[1]. In Vitro Suprofen (TN-762) is an NSAID. Suprofen (TN-762) is an ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. suprofen was clinically effective but the Page 1 of 2 www.MedChemExpress.com differential suppression of prostanoids favors 200mg which spares 6-keto PGF1a[1].
    [Show full text]
  • Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer
    pharmaceutics Review Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer Sibusiso Alven, Xhamla Nqoro , Buhle Buyana and Blessing A. Aderibigbe * Department of Chemistry, University of Fort Hare, Alice Eastern Cape 5700, South Africa; [email protected] (S.A.); [email protected] (X.N.); [email protected] (B.B.) * Correspondence: [email protected] Received: 24 November 2019; Accepted: 30 December 2019; Published: 29 April 2020 Abstract: Cancer is a chronic disease that is responsible for the high death rate, globally. The administration of anticancer drugs is one crucial approach that is employed for the treatment of cancer, although its therapeutic status is not presently satisfactory. The anticancer drugs are limited pharmacologically, resulting from the serious side effects, which could be life-threatening. Polymer drug conjugates, nano-based drug delivery systems can be utilized to protect normal body tissues from the adverse side effects of anticancer drugs and also to overcome drug resistance. They transport therapeutic agents to the target cell/tissue. This review article is based on the therapeutic outcomes of polymer-drug conjugates against breast and lung cancer. Keywords: breast cancer; lung cancer; chemotherapy; polymer-based carriers; polymer-drug conjugates 1. Introduction Cancer is a chronic disease that leads to great mortality around the world and cancer cases are rising continuously [1]. It is the second cause of death worldwide, followed by cardiovascular diseases [2]. It is characterized by an abnormal uncontrolled proliferation of any type of cells in the human body [3]. It is caused by external factors, such as smoking, infectious organisms, pollution, and radiation; it is also caused by internal factors, such as immune conditions, hormones, and genetic mutation [3].
    [Show full text]
  • What Is Medicinal Chemistry
    Unit 1 Prepared By: Neetu Sabarwal Department of Pharmaceutical Chemistry SOS Pharmaceutical Sciences Jiwaji University. Gwalior Content INTRODUCTION TO MEDICINAL CHEMISTRY • History and development of medicinal chemistry Physicochemical properties in relation to biological action • Ionization, Solubility, Partition Coefficient, Hydrogen bonding, Protein binding, Chelation, • Bioisosterism, Optical and Geometrical isomerism. Drug metabolism • Drug metabolism principles- Phase I and Phase II. • Factors affecting drug metabolism including stereo chemical aspects. CHEMISTRY What is Chemistry? • Chemistry is known as the central of science. • It is a branch of physical science that studies the composition, structure, properties and changes of matter. • MATTER = Solid / Liquid/ Gas. BRANCHES OF CHEMISTRY PHYSICAL CHEMISTRY • the branch of chemistry concerned with the application of the techniques and theories of physics to the study of chemical systems. • Branches : chemical Kinetics, Electrochemistry, spectroscopy, photochemistry. INORGANIC CHEMISTRY • deals with the synthesis and behaviour of inorganic and organometallic compounds • Branches :Bioinorganic, Cluster, Material & Nuclear Chemistry ORGANIC CHEMISTRY • study of the structure, properties, and reactions of organic compounds and organic materials, i.e., matter in its various forms that contain carbon atoms. • Branches : Biochemistry, biophysical, Biorganic, P’ceutical, Medicinal WHAT IS MEDICINAL CHEMISTRY • It is a discipline or intersection of chemistry especially synthetic organic
    [Show full text]
  • Targeting Drug Delivery with Light: a Highly Focused Approach
    Advanced Drug Delivery Reviews 171 (2021) 94–107 Contents lists available at ScienceDirect Advanced Drug Delivery Reviews journal homepage: www.elsevier.com/locate/addr Targeting drug delivery with light: A highly focused approach Teresa L. Rapp a,ColeA.DeForesta,b,c,d,e,⁎ a Department of Chemical Engineering, University of Washington, Seattle, WA 98105, USA b Department of Bioengineering, University of Washington, Seattle, WA 98105, USA c Department of Chemistry, University of Washington, Seattle, WA 98105, USA d Institute of Stem Cell & Regenerative Medicine, University of Washington, Seattle, WA 98109, USA e Molecular Engineering & Sciences Institute, University of Washington, Seattle, WA 98105, USA article info abstract Article history: Light is a uniquely powerful tool for controlling molecular events in biology. No other external input (e.g., heat, Received 16 October 2020 ultrasound, magnetic field) can be so tightly focused or so highly regulated as a clinical laser. Drug delivery vehi- Received in revised form 4 January 2021 cles that can be photonically activated have been developed across many platforms, from the simplest “caging” of Accepted 8 January 2021 therapeutics in a prodrug form, to more complex micelles and circulating liposomes that improve drug uptake Available online 22 January 2021 and efficacy, to large-scale hydrogel platforms that can be used to protect and deliver macromolecular agents in- cluding full-length proteins. In this Review, we discuss recent innovations in photosensitive drug delivery and Keywords: Photochemistry highlight future opportunities to engineer and exploit such light-responsive technologies in the clinical setting. Photoactivated ©2021ElsevierB.V.Allrightsreserved. Light-mediated delivery In vivo drug delivery Photodegradable hydrogels Photoresponsive nanoparticles Prodrugs Dual-action Photoswitches Contents 1.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,472,433 B2 Wechter (45) Date of Patent: Oct
    USOO6472433B2 (12) United States Patent (10) Patent No.: US 6,472,433 B2 Wechter (45) Date of Patent: Oct. 29, 2002 (54) METHOD FOR TREATMENT OF Variability of Inversion of (R)-Flurbiprofen in Different NFLAMMATION WITH R-NSAIDS Species, Sabine Menzel-Soglowek, Gerd Geisslinger, Win fried S. Beck, and Kay Brune-Journal of Pharmaceutical (75) Inventor: William J. Wechter, Ojai, CA (US) Sciences vol. 81, No. 9, Sep. 1992. Disposition and Pharmacokinetics of R-flurbiprofen in (73) Assignee: Loma Linda University Medical Three Species: Demonstration of R- to S-Flurbiprofen Center, Loma Linda, CA (US) Inversion in the Mouse, Rat and Monkey-William J. Wechter, E. David Murray, Jr. Karina M. Gibson, David D. (*) Notice: Subject to any disclaimer, the term of this Quiggle, and Douglas L. Leipold-Laboratory of Chemical patent is extended or adjusted under 35 Endocrinology, Loma Linda University School of Medicine, U.S.C. 154(b) by 0 days. 1998. Superaspirin, Jerome Groopman The New Yorker, Jun. 15, (21) Appl. No.: 09/797,022 1998 pp. 32–35. (22) Filed: Mar. 1, 2001 Building a Better Aspirin, Science, vol. 280, May 22, 1998. (65) Prior Publication Data R-Flurbiprofen Chemoprevention and Treatment of Intesti nal Adenomas in the APC Min/+ Mouse Model: Implica US 2001/0012849 A1 Aug. 9, 2001 tions for Prophylazis and Treatment of Colon Caner, Will iam Wechter, Darko Kantoci, E. David Murray, Jr. David D. Related U.S. Application Data Quiggle, Douglas D. Leipold, Karina M. Gibson, and John D. McCracker-Cancer Research 57, 4316-4324, Oct. 1, (63) Continuation of application No.
    [Show full text]
  • From Phenotypic Hit to Chemical Probe: Chemical Biology Approaches to Elucidate Small Molecule Action in Complex Biological Systems
    molecules Review From Phenotypic Hit to Chemical Probe: Chemical Biology Approaches to Elucidate Small Molecule Action in Complex Biological Systems Quentin T. L. Pasquer , Ioannis A. Tsakoumagkos and Sascha Hoogendoorn * Department of Organic Chemistry, University of Geneva, Quai Ernest-Ansermet 30, 1211 Genève, Switzerland; [email protected] (Q.T.L.P.); [email protected] (I.A.T.) * Correspondence: [email protected]; Tel.: +41-223796085 Academic Editor: Steven Verhelst Received: 9 November 2020; Accepted: 1 December 2020; Published: 3 December 2020 Abstract: Biologically active small molecules have a central role in drug development, and as chemical probes and tool compounds to perturb and elucidate biological processes. Small molecules can be rationally designed for a given target, or a library of molecules can be screened against a target or phenotype of interest. Especially in the case of phenotypic screening approaches, a major challenge is to translate the compound-induced phenotype into a well-defined cellular target and mode of action of the hit compound. There is no “one size fits all” approach, and recent years have seen an increase in available target deconvolution strategies, rooted in organic chemistry, proteomics, and genetics. This review provides an overview of advances in target identification and mechanism of action studies, describes the strengths and weaknesses of the different approaches, and illustrates the need for chemical biologists to integrate and expand the existing tools to increase the probability of evolving screen hits to robust chemical probes. Keywords: phenotypic screening; target identification; mechanism of action; drug discovery; chemical probes; photo-affinity labeling; proteomics; genetic screens; resistance cloning 1.
    [Show full text]
  • Discovery of Drug Mode of Action and Drug Repositioning from Transcriptional Responses
    Discovery of drug mode of action and drug repositioning from transcriptional responses Francesco Iorioa,b, Roberta Bosottic, Emanuela Scacheric, Vincenzo Belcastroa, Pratibha Mithbaokara, Rosa Ferrieroa, Loredana Murinob, Roberto Tagliaferrib, Nicola Brunetti-Pierria,d, Antonella Isacchic,1, and Diego di Bernardoa,e,1 aTeleThon Institute of Genetics and Medicine, Naples, Italy; cDepartment of Biotechnology, Nerviano Medical Sciences, Milan, Italy; eDepartment of Systems and Computer Science, “Federico II” University of Naples, Naples, Italy; dDepartment of Pediatrics, “Federico II” University of Naples, Naples, Italy; and bDepartment of Mathematics and Computer Science, University of Salerno, Salerno, Italy Edited by Charles R. Cantor, Sequenom, Inc., San Diego, CA, and approved July 2, 2010 (received for review January 5, 2010) A bottleneck in drug discovery is the identification of the molecular tivity Map” (11, 12). These compound-specific expression profiles targets of a compound (mode of action, MoA) and of its off-target can be queried with a gene signature to recover a subset of effects. Previous approaches to elucidate drug MoA include analy- compounds connected to the signature of interest. A compound sis of chemical structures, transcriptional responses following is selected if genes in the signature are significantly modulated in treatment, and text mining. Methods based on transcriptional the compound-specific transcriptional response. If a gene signa- responses require the least amount of information and can be ture for a new compound is available, it is then possible to search quickly applied to new compounds. Available methods are ineffi- the collection of transcriptional responses with that signature to cient and are not able to support network pharmacology.
    [Show full text]